Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2010. The report specifically addresses the notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan transactions.
- Share Price (Ordinary): £11.42
- Share Price (ADR): $34.91
- Dividend Re-investment Date: July 8, 2010
Material Changes
On July 13, 2010, the Administrators of the Performance Share Plan notified the Company of an increase in notional interests for various participants. This increase resulted from the notional re-investment of the dividend paid to shareholders on July 8, 2010.
Guidance, Outlook, and Risks
The filing does not contain management commentary, future guidance, or risk factors. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period. The notification complies with Disclosure and Transparency Rules 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the vesting schedule and conditions for the GlaxoSmithKline Performance Share Plan to understand future payout obligations.
- Confirm the total number of shares and ADRs issued to directors and connected persons listed in the filing.
- Review the dividend payment details for July 8, 2010, to validate the re-investment calculation basis.